Drug Information



Brand Name:PemetrexedTrade Name:alimta
FDA Approved For:ALIMTA in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery.Pediatric Use:The safety and effectiveness of ALIMTA in pediatric patients have not been established.
Carcinogen:No carcinogenicity studies have been conducted with Pemetrexed.Mutagen:Pemetrexed was clastogenic in the in vivo micronucleus assay in mouse bone marrow but was not mutagenic in multiple in vitro tests (Ames assay, CHO cell assay).
Manufacturer and/or Distributor:Eli Lilly and Company

Adverse Reactions:

See Table 3 of insert. (Use link for more information))

More Information